` Comparison: VY4 vs AZN - Alpha Spread

VY4
vs
AZN

Over the past 12 months, VY4 has underperformed AZN, delivering a return of -15% compared to the AZN's +21% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
VY4
AZN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

VY4 Intrinsic Value
0.942 EUR
Overvaluation 23%
Intrinsic Value
Price
AZN Intrinsic Value
7 870.67 GBX
Overvaluation 45%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
SNDL Inc
F:VY4
1.231 EUR
AstraZeneca PLC
LSE:AZN
14 374 GBX
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
VY4, AZN

VY4
AZN
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
SNDL Inc
Revenue
AstraZeneca PLC
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
VY4, AZN

VY4
AZN
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
SNDL Inc
F:VY4
AstraZeneca PLC
LSE:AZN
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

VY4
27%
AZN
81.3%
LTM 3Y Avg 5Y Avg 10Y Avg
SNDL Inc
AstraZeneca PLC

Operating Margin

VY4
-1.2%
AZN
23.9%
LTM 3Y Avg 5Y Avg 10Y Avg
SNDL Inc
AstraZeneca PLC

Net Margin

VY4
-9.7%
AZN
17.4%
LTM 3Y Avg 5Y Avg 10Y Avg
SNDL Inc
AstraZeneca PLC

FCF Margin

VY4
6.1%
AZN
14.8%
LTM 3Y Avg 5Y Avg 10Y Avg
SNDL Inc
AstraZeneca PLC

ROE

VY4
-8%
AZN
22.9%
LTM 3Y Avg 5Y Avg 10Y Avg
SNDL Inc
AstraZeneca PLC

ROA

VY4
-6.7%
AZN
9.4%
LTM 3Y Avg 5Y Avg 10Y Avg
SNDL Inc
AstraZeneca PLC

ROIC

VY4
-1%
AZN
13%
LTM 3Y Avg 5Y Avg 10Y Avg
SNDL Inc
AstraZeneca PLC

ROCE

VY4
-0.9%
AZN
17.6%
LTM 3Y Avg 5Y Avg 10Y Avg
SNDL Inc
AstraZeneca PLC

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
VY4, AZN

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
VY4, AZN

Loading
VY4
AZN
Difference
www.alphaspread.com

Performance By Year
VY4, AZN

Loading
VY4
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare VY4 to other stocks
LLY
Eli Lilly and Co
More expensive
vs VY4
JNJ
Johnson & Johnson
More expensive
vs VY4
ROG
Roche Holding AG
Cheaper
vs VY4
NOVN
Novartis AG
Cheaper
vs VY4
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett